Last edition
News about "antibody-drug conjugates (ADCs"
Biocytogen Grants Licence for RenNano Platform to Taisho Pharmaceutical
Biocytogen licenses its RenNano platform to Taisho Pharmaceutical to advance fully human heavy chain-only antibody discovery, supporting in-vivo screening and downstream research.
Antibody-Drug Conjugates (ADCs) | 31/03/2026 | By News Bureau
GV20 Therapeutics Hits Milestone in ADC Collaboration with Mitsubishi Tanabe Pharma
GV20 Therapeutics has secured a milestone payment from Mitsubishi Tanabe Pharma under their 2025 collaboration to develop the first-in-class Antibody Drug Conjugates (ADCs) using GV20’s STEAD AI–discovered tumour-targeting antibodies.
Antibody Drug Conjugates (ADCs) | 28/11/2025 | By Dineshwori | 191
Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration
Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.
Antibody-drug Conjugates (ADCs | 24/11/2025 | By Dineshwori | 197
Hikal Launches New High Potency API Laboratory at its Pune Integrated Innovation Centre
Hikal has inaugurated an advanced High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at its Integrated Innovation Centre in Pune, further strengthening its end-to-end CDMO capabilities and enhancing its ability to safely develop, test and deliver highly potent compounds for the global pharmaceutical industry.
Antibody Drug Conjugates (ADCs) | 14/10/2025 | By Dineshwori | 336
Turbine Partners with AstraZeneca to Accelerate Antibody-Drug Conjugate Discovery
Turbine, a leading company specialising in virtualising biological experiments through artificial intelligence (AI), has announced a new collaboration with AstraZeneca to enhance the discovery of antibody-drug conjugates (ADCs).
Antibody-drug Conjugates (ADCs) | 09/10/2025 | By Dineshwori | 248
Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia
The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.
Antibody-drug Conjugates (ADCs) | 17/09/2025 | By Dineshwori | 161
Cohance's Jaggaiahpet API Plant Clears USFDA Inspection with Zero 483 Observations
The United States Food and Drug Administration (USFDA) has completed a general current Good Manufacturing Practices (cGMP) audit at Cohance Lifesciences' API manufacturing facility (API Unit1) located at Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations.
Antibody Drug Conjugates (ADCs) | 12/09/2025 | By Dineshwori | 407
Samsung Biologics has announced its financial results for the second quarter of fiscal year 2025, posting strong growth across both consolidated and standalone metrics.
Antibody-drug Conjugates (ADCs | 23/07/2025 | By Dineshwori | 1385
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy